Cargando…
223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy
BACKGROUND: Bone-seeking radiopharmaceuticals can deposit radiation selectively to some osteosarcoma tumours because of the bone-forming nature of this cancer. OBJECTIVES: This is the first report of using 223-radium, an alpha-emitting calcium analogue with a high therapeutic index, in combination t...
Autores principales: | Anderson, Pete M, Scott, Jacob, Parsai, Shireen, Zahler, Stacey, Worley, Sarah, Shrikanthan, Sankaran, Subbiah, Vivek, Murphy, Erin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199915/ https://www.ncbi.nlm.nih.gov/pubmed/32303572 http://dx.doi.org/10.1136/esmoopen-2019-000635 |
Ejemplares similares
-
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
por: Anderson, Peter M., et al.
Publicado: (2022) -
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
por: Takalkar, Amol, et al.
Publicado: (2014) -
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 and bone metastatic disease: still more to learn
por: Sartor, Oliver
Publicado: (2023)